A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells

2025/03/07 by Marisa Mercadante, Armin Scheben, Jacob Estrada +11 · 1 voice
Immunology and Microbiology · Medicine · #Immune Cell Function and Interaction #Immune cells in cancer #Cancer Immunotherapy and Biomarkers

paper · doi:10.1101/2025.03.06.641285

openalex publication_date 2025/03/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15

Abstract

Intratumoral heterogeneity drives therapy resistance and relapses in advanced stage cancers, such as ovarian cancer. Here, we present a live cell imaging assay using patient-derived ovarian cancer organoids for real time capture and quantification of natural killer cell-mediated apoptotic events in >500 organoids simultaneously. Our assay revealed significant inter- and intratumor response heterogeneity and identified a rare resistant organoid population, opening avenues to test immunomodulatory strategies that overcome resistance.

Citations

• High-throughput imaging: Focusing in on drug discovery in 3D
• A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity

Discussions

• A patient-derived ovarian cancer organoid platform to study susceptibility to NK cells doi.org/10.1101/2025... [bsky, 2 points, 0 comments]

Related

• Natural killer cells in cancer biology and therapy
• A novel serous ovarian carcinoma model induced by DMBA: Results from OncoTherad® (MRB-CFI-1) immunotherapy preclinical testing
• Exploring The Contribution of Innate Immune Cells to Breast Cancer Immunotherapy
• Efficacy Evaluation of “Enhanced” Natural Killers with CISH and B2M Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients
• A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids